Cyclerion Therapeutics Inc (CYCN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has a cash flow conversion efficiency ratio of -0.174x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.58 Million) by net assets ($9.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cyclerion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Cyclerion Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Cyclerion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schweizer Electronic AG
F:SCE
|
-0.372x |
|
Straker Ltd
AU:STG
|
-0.113x |
|
Spring Art Holdings Bhd
KLSE:0216
|
0.013x |
|
Turmalina Metals Corp
V:TBX
|
0.012x |
|
Smith Micro Software Inc
NASDAQ:SMSI
|
-0.107x |
|
Zantat Holdings Berhad
KLSE:0301
|
0.023x |
|
Pursuit Minerals Ltd
AU:PUR
|
-0.019x |
|
Avecho Biotechnology Limited
F:OEZ
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Cyclerion Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.09 Million | $-3.31 Million | -0.365x | +25.50% |
| 2024-12-31 | $8.85 Million | $-4.33 Million | -0.490x | +73.99% |
| 2023-12-31 | $11.29 Million | $-21.25 Million | -1.882x | +51.56% |
| 2022-12-31 | $10.45 Million | $-40.61 Million | -3.885x | -413.35% |
| 2021-12-31 | $48.25 Million | $-36.52 Million | -0.757x | +37.88% |
| 2020-12-31 | $59.49 Million | $-72.49 Million | -1.218x | -16.50% |
| 2019-12-31 | $97.73 Million | $-102.22 Million | -1.046x | -111.20% |
| 2018-12-31 | $-10.45 Million | $-97.50 Million | 9.335x | -1.53% |
| 2017-12-31 | $-8.57 Million | $-81.22 Million | 9.480x | +28.52% |
| 2016-12-31 | $-6.76 Million | $-49.87 Million | 7.377x | -- |
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a sy… Read more